Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-host Disease

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT

Bone Marrow Transplantation volume 50, pages 106–112 (2015)Cite this article

Subjects

Abstract

We performed a retrospective analysis of the outcome of 197 consecutive unrelated donor transplant recipients who received GVHD prophylaxis either TM regimen (tacrolimus and mycophenolate) (121 patients) or TM/ATG-G regimen (TM with low-dose antithymocyte globulin (ATG) of 4.5 mg/kg, ATG-G, Genzyme) (76 patients). Cumulative incidences of grade II-IV acute GVHD for the TM and TM/ATG-G cohorts were 49% and 61% (P=0.11) and grade III-IV acute GVHD for the TM and TM/ATG-G cohorts were 27% and 14% (P=0.02), respectively. There was no difference in the incidence of relapse or disease progression between TM and TM/ATG-G—16% and 23% (P=0.64). TM/ATG-G cohort had lower incidence of non-relapse mortality (NRM; 37% vs 20%, P=0.01), chronic GVHD (56% vs 43%, P<0.001) and more favorable global chronic GVHD severity (P<0.001). Univariate analyses showed improved OS and PFS of patients who received TM/ATG-G. Multivariate analysis confirmed TM/ATG-G had a favorable influence on OS (P=0.05) but not on PFS (P=0.07). We concluded that low-dose ATG of 4.5 mg/kg given in conjunction with TM improved GVHD prophylaxis without increased risk of relapse. Lower NRM, lower incidence and severity of chronic GVHD could potentially improve survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Dicke KA, Tridente G, van Bekkum DW . The selective elimination of immunologically competent cells from bone marrow and lymphocyte cell mixtures. 3. In vitro test for detection of immunocompetent cells in fractionated mouse spleen cell suspensions and primate bone marrow suspensions. Transplantation 1969; 8: 422–434.

    Article  CAS  PubMed  Google Scholar 

  2. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996–4003.

    CAS  PubMed  Google Scholar 

  3. Remberger M, Storer B, Ringden O,, Anasetti C . Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002; 29: 391–397.

    Article  CAS  PubMed  Google Scholar 

  4. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816–824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ratanatharathorn V, Pavletic S, Uberti JP . Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat Rev 2009; 35: 653–661.

    Article  CAS  PubMed  Google Scholar 

  6. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.

    Article  CAS  PubMed  Google Scholar 

  7. Mohty M . Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387–1394.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1734–1744.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  11. Kaplan EL, Meier P . Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  13. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  14. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. [Review] [20 refs]. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  15. Cox DR . Regression models and life-tables. J R Stat Soc B 1972; 34: 187–220.

    Google Scholar 

  16. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988; 16: 1141–1154.

    Article  Google Scholar 

  18. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054.

    CAS  PubMed  Google Scholar 

  19. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495–505.

    Article  CAS  PubMed  Google Scholar 

  20. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006; 12: 217–225.

    Article  CAS  PubMed  Google Scholar 

  21. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  PubMed  Google Scholar 

  22. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010; 16: 937–947.

    Article  CAS  PubMed  Google Scholar 

  23. Ram R, Yeshurun M, Vidal L, Shpilberg O, Gafter-Gvili A . Mycophenolate mofetil vs methotrexate for the prevention of graft-versus-host-disease–systematic review and meta-analysis. Leuk Res 2014; 38: 352–360.

    Article  CAS  PubMed  Google Scholar 

  24. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507–1515.

    Article  CAS  PubMed  Google Scholar 

  25. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012; 367: 135–145.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012; 119: 6145–6154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013; 122: 1510–1517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  PubMed  Google Scholar 

  29. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.

    Article  PubMed  Google Scholar 

  30. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.

    Article  CAS  PubMed  Google Scholar 

  31. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius. Blood 2011; 117: 6375–6382.

    Article  PubMed  Google Scholar 

  32. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T et al. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. Biol Blood Marrow Transplant 2011; 17: 1698–1703.

    Article  CAS  PubMed  Google Scholar 

  34. Devillier R, Crocchiolo R, Castagna L, Furst S, El Cheikh J, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639–645.

    Article  CAS  PubMed  Google Scholar 

  35. Devillier R, Furst S, El-Cheikh J, Castagna L, Harbi S, Granata A et al. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 370–374.

    Article  CAS  PubMed  Google Scholar 

  36. Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 281–286.

    Article  CAS  PubMed  Google Scholar 

  37. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 920–926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328–336.

    Article  CAS  PubMed  Google Scholar 

  39. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601–1605.

    Article  CAS  PubMed  Google Scholar 

  40. Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK et al. Prophylaxis with sirolimus and tacrolimus +/- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 916–922.

    Article  CAS  PubMed  Google Scholar 

  41. Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531–537.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012; 97: 1882–1889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Jim HSL, Barata A, Small BJ, Jacobsen PB, Pidala J . Quality of life associated with sirolimus for prevention of graft versus host disease: results from a randomized trial. Haematologica 2014; 99: 548–553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 1422–1430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Remberger M, Svahn BM, Mattsson J, Ringden O . Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122–127.

    CAS  PubMed  Google Scholar 

  46. Remberger M, Ringden O, Hagglund H, Svahn BM, Ljungman P, Uhlin M et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant. 2013; 27: E368–E374.

    Article  CAS  PubMed  Google Scholar 

  47. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D et al. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma 2012; 53: 915–919.

    Article  CAS  PubMed  Google Scholar 

  48. Dulery R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M et al. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 2014; 20: 646–654.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Blood and Marrow Stem Cell Transplantation Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA

    V Ratanatharathorn, A Deol, L Ayash, S Cronin, D Bhutani, L G Lum, M Abidi, M Ventimiglia, K Mellert & J P Uberti

Authors
  1. V Ratanatharathorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Deol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Ayash
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Cronin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Bhutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L G Lum
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Abidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Ventimiglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Mellert
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J P Uberti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Ratanatharathorn.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ratanatharathorn, V., Deol, A., Ayash, L. et al. Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50, 106–112 (2015). https://doi.org/10.1038/bmt.2014.203

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.203

This article is cited by

Search

Advanced search

Quick links